|
|
Savannah House, 11 Charles II Street
London, SW1Y 4QU England
phone:44 (0) 207 451 2478
fax:44 (0) 207 451 2469
|
|
| Symbol |
EBOI |
| Exchange |
.PK |
| Founded |
0 |
| Employees |
|
|
|
| www.enhancebiotech.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Commercialisation of "Lifestyle Drugs" with focus on Male Sexual Dysfunction and Dermatology. |
|
| Management |
| Chris Every, Chief Executive Officer
Dr Sam McCormick, Scientific Advisor
Linden J. Boyne, Chief Financial Officer & Secretary |
| |
|
|
|
|
|
|
|
| Keywords |
| sexual dysfunction, impotence, dermatology, premature ejaculation, cellulite, psoriasis, aging, hiving, HIVAIDS |
|
|
|
| Description |
|
Enhance Biotech is engaged in acquisition, development and commercialisation of "Lifestyle Drugs" in the main therapeutic lifestyle disorder categories. Their focus is on two main therapuetic areas, Male Sexual Dysfunction and Dermatology.The company belongs to a new generation of healthcare specialists focused on developing products that address 'wellbeing' - treatments for chronic long-term conditions that are not necessarily life threatening, but can severely affect the quality of life. They have a pipeline of drugs at all stages of development and a flexible approach to commercialistion. |
|
| Products / Services |
LI 301, Premature EjaculationLI316a and LI316b are compounds which provide the ability to immobilise in suspended animation and re-mobilise mammalian sperm.LI303 is a new product which acts on the cell structures and collagen fiber network underlying the skin to reduce the rippled appearance of cellulite on the surface of the skin.LI312 is a topical treatment in development for the future treatment of moderate to severe psoriasis.LI236 is a compound which provides scope to counteract commonly experienced symptoms of the ageing process.LI412 is a topically applied treatment being developed to relieve the symptoms of chronic hiving.
|
|
| Market / Customers |
The main therapeutic areas targeted by Enhance Biotech include sexual dysfunction, fertility enhancement , skin disorders and anti-aging, and have a combined forecast market potential in excess of $32 billion by 2008 according to a 2004 report on Lifestyle drugs published by Reuters. Add to this the industry's spend on lifestyle drug development in the last ten years which exceeds $20 billion, the high potential of this sector is well demonstrated.
|
|
| Strategy |
The Enhance Biotech product portfolio focuses on meeting the unmet need in core sectors of the lifestyle market and in many cases is developing platform products with potential ongoing development for related indications too.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
